Description
In less than a month, a clinical trial for 700 people living with excess weight will reach its end with potentially profound implications for the size of both British waistlines and the profit margins of the world’s two biggest drug companies.
This week, the wider benefits of weight-loss jabs were in the spotlight after the UK Government said the injections including Mounjaro – set to be rolled out to 1.6 million patients on the NHS over the next 12 years – could be given to unemployed people to help get them back into work.
But as rival drug companies battle to capture market share of what is likely to prove one of the most lucrative pharmaceutical products in recent medical history, consumers and governments alike will want to know which jab is best.
Reviews
There are no reviews yet.